Kenvue Inc. (NYSE:KVUE) Shares Bought by Sender Co & Partners Inc.

Sender Co & Partners Inc. increased its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 315.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,302 shares of the company's stock after purchasing an additional 80,736 shares during the period. Kenvue makes up 2.1% of Sender Co & Partners Inc.'s holdings, making the stock its 12th biggest position. Sender Co & Partners Inc.'s holdings in Kenvue were worth $2,270,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the business. Handelsbanken Fonder AB raised its stake in shares of Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock worth $15,846,000 after buying an additional 21,222 shares during the period. Alberta Investment Management Corp raised its stake in shares of Kenvue by 23.2% during the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after buying an additional 109,700 shares during the period. Longbow Finance SA raised its stake in shares of Kenvue by 5.0% during the 4th quarter. Longbow Finance SA now owns 280,568 shares of the company's stock worth $5,990,000 after buying an additional 13,287 shares during the period. Steward Partners Investment Advisory LLC increased its stake in shares of Kenvue by 143.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock worth $1,023,000 after purchasing an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. increased its stake in shares of Kenvue by 1.4% during the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock worth $26,754,000 after purchasing an additional 17,466 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 0.6%

NYSE:KVUE traded up $0.15 on Tuesday, hitting $24.15. The stock had a trading volume of 16,356,929 shares, compared to its average volume of 16,484,570. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $46.34 billion, a price-to-earnings ratio of 45.57, a PEG ratio of 2.62 and a beta of 1.02. The company has a fifty day moving average price of $23.18 and a two-hundred day moving average price of $22.60. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Kenvue's revenue was down 3.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.28 EPS. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date is Wednesday, May 14th. Kenvue's payout ratio is 149.09%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on KVUE shares. Redburn Atlantic started coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. Citigroup boosted their target price on shares of Kenvue from $22.00 to $24.50 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. UBS Group boosted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Friday, May 9th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.